Syngene International Limited , a leading contract research and manufacturing services company, has reported strong financial results for the first quarter of fiscal year 2026, demonstrating solid growth across key metrics.

Financial Highlights

Syngene International Limited reported the following results for the quarter ended June 30, 2025:

Standalone Results

Consolidated Results

Operational Highlights

During the quarter, the company capitalized Rs 3,438.00 million as property, plant and equipment after receiving licenses for:

• Drug substance production line
• Bonded warehouse at its Bangalore biologics facility

Management Changes

The company appointed Mr. Chethan Yogesh as Company Secretary and Compliance Officer effective July 23, 2025. Key details about Mr. Yogesh:

• Fellow Member of the Institute of Company Secretaries of India
• Over 16 years of experience in corporate governance and compliance

Dividend Announcement

The Board of Directors recommended a final dividend of Rs 1.25 per equity share, subject to shareholder approval.

Outlook

Syngene International continues to demonstrate strong performance in the contract research and manufacturing services sector. The company's investments in infrastructure and human resources position it well for future growth opportunities.

As Syngene International moves forward, it remains committed to delivering value to its shareholders while maintaining its focus on innovation and quality in its services.

Syngene International , a leading contract research organization, has achieved significant milestones in its regulatory compliance efforts. The company recently announced positive updates from the United States Food and Drug Administration (USFDA) for two of its facilities in Bengaluru.

USFDA Inspection Outcomes

Semicon Park Facility

• Passed a Good Clinical Practice (GCP) inspection with zero observations
• Classified as 'No Action Indicated'

Biocon Park SEZ Facility

• Received an Establishment Inspection Report (EIR)
• Classified as 'Voluntary Action Indicated'
• USFDA accepted the company's Corrective and Preventive Action (CAPA) plans

Implications for Syngene International

These positive outcomes from the USFDA inspections are significant for Syngene International:

1. Regulatory Compliance: The successful inspections demonstrate that the facilities meet the USFDA's rigorous requirements.
2. Quality Assurance: The results validate the manufacturing processes and quality control measures at the Bengaluru facilities.
3. Operational Continuity: The company stated that these outcomes are not expected to impact its financials or operations.
4. Client Confidence: The positive USFDA updates may boost client confidence in Syngene International's capabilities.

About Syngene International

Syngene International is a prominent integrated research, development, and manufacturing services company. It provides a range of services to global pharmaceutical, biotechnology, nutrition, and consumer goods companies. These recent USFDA updates for its Bengaluru facilities further strengthen its position in the contract research and manufacturing space.

The positive outcomes from the USFDA inspections mark significant achievements for Syngene International, potentially reinforcing its commitment to maintaining high-quality standards and regulatory compliance in its operations.